{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:22:13Z","timestamp":1788880933792,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":946,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54 GM115428"],"award-info":[{"award-number":["U54 GM115428"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM121334"],"award-info":[{"award-number":["P20 GM121334"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM104357"],"award-info":[{"award-number":["P20 GM104357"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R00 MD014738"],"award-info":[{"award-number":["R00 MD014738"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001011","name":"Joe and Dorothy Dorsett Brown Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54 GM115428"],"award-info":[{"award-number":["U54 GM115428"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM121334"],"award-info":[{"award-number":["P20 GM121334"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM104357"],"award-info":[{"award-number":["P20 GM104357"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R00 MD014738"],"award-info":[{"award-number":["R00 MD014738"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001011","name":"Joe W. and Dorothy Dorsett Brown Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) is one of the leading causes of cardiovascular morbidity and mortality. HF with preserved ejection fraction (HFpEF), or diastolic failure, accounts for half of all HF cases and differs from HF with reduced ejection fraction (HFrEF). Patients with HFpEF are typically older, female, and commonly seen with chronic kidney disease (CKD), one of the leading independent risk factors for mortality in these patients. Unfortunately, drugs that had shown significant improvements in mortality in HFrEF have not shown similar benefits in HFpEF. Recently, sodium glucose transporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular morbidity and mortality in HFrEF patients and slow down CKD progression. This study aimed to elucidate the impact of this drug class on mortality and risk of end stage renal disease in patients with HFpEF, which is currently unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We retrospectively analysed the Research Data Warehouse containing electronic health records from de-identified patients (n = 1 266 290) from the University of Mississippi Medical Center from 2013 to 2022. HFpEF patients had an average follow-up of 4 \u00b1 2 years. Factors associated with increased all-cause mortality during HFpEF included age, male sex, and CKD. Interestingly, the only treatments associated with significant improvements in survival were angiotensin converting enzyme inhibitors\/angiotensin receptor blockers and SGLT2i, regardless of CKD or diabetes status. Additionally, SGLT2i use was also associated with significant decrease in the risk of end stage renal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results support the use of SGLT2i in an HFpEF population with relatively high rates of hypertension, CKD, and black race and suggests that improvements in mortality may be through preserving kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14347","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:44:03Z","timestamp":1681267443000},"page":"2010-2018","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Retrospective Analysis of SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-2960","authenticated-orcid":false,"given":"John S.","family":"Clemmer","sequence":"first","affiliation":[{"name":"Department of Physiology, University of Mississippi Medical Center , Jackson, MS, 39216 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Data Science, University of Mississippi Medical Center , Jackson, MS, 39216 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth T.","family":"Lirette","sequence":"additional","affiliation":[{"name":"Department of Data Science, University of Mississippi Medical Center , Jackson, MS, 39216 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"2026012114101801700_ehf214347-bib-0001","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke Statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"2026012114101801700_ehf214347-bib-0002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114101801700_ehf214347-bib-0003","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114101801700_ehf214347-bib-0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026012114101801700_ehf214347-bib-0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026012114101801700_ehf214347-bib-0006","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0008","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(21)01242-3","article-title":"FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?","volume":"398","author":"Jafar","year":"2021","journal-title":"Lancet"},{"key":"2026012114101801700_ehf214347-bib-0009","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0011","article-title":"University of Mississippi Medical Center, Center for Informatics and Analytics. Patient cohort","author":"UMMC","year":"2020","journal-title":"Explorer"},{"key":"2026012114101801700_ehf214347-bib-0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0013","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0014","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.685996","article-title":"Predominance of heart failure with preserved ejection fraction in postmenopausal women: intra- and extra-cardiomyocyte maladaptive alterations Scaffolded by estrogen deficiency","volume":"9","author":"Adekunle","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026012114101801700_ehf214347-bib-0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026012114101801700_ehf214347-bib-0016","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026012114101801700_ehf214347-bib-0017","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"Lofman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114101801700_ehf214347-bib-0018","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-138-11-200306030-00013","article-title":"Pharmacotherapy for heart failure in patients with renal insufficiency","volume":"138","author":"Shlipak","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026012114101801700_ehf214347-bib-0019","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","article-title":"Renal function as a predictor of outcome in a broad spectrum of patients with heart failure","volume":"113","author":"Hillege","year":"2006","journal-title":"Circulation"},{"key":"2026012114101801700_ehf214347-bib-0020","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphys.2019.01108","article-title":"Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets","volume":"10","author":"van de Wouw","year":"2019","journal-title":"Front Physiol"},{"key":"2026012114101801700_ehf214347-bib-0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026012114101801700_ehf214347-bib-0022","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"2026012114101801700_ehf214347-bib-0023","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"2026012114101801700_ehf214347-bib-0024","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2013.10.032","article-title":"Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study)","volume":"113","author":"Chang","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012114101801700_ehf214347-bib-0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004457","article-title":"Racial differences in characteristics and outcomes of patients with heart failure and preserved ejection fraction in the treatment of preserved cardiac function heart failure trial","volume":"11","author":"Lewis","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012114101801700_ehf214347-bib-0026","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1016\/j.jacc.2022.04.031","article-title":"Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure","volume":"79","author":"Faridi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012114101801700_ehf214347-bib-0027","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jchf.2021.05.010","article-title":"Forgone medical care associated with increased health care costs among the U.S. heart failure population","volume":"9","author":"Thomas","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012114101801700_ehf214347-bib-0028","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0029","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114101801700_ehf214347-bib-0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of beta-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026012114101801700_ehf214347-bib-0031","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1038\/s41598-018-27799-y","article-title":"Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction","volume":"8","author":"Tsujimoto","year":"2018","journal-title":"Sci Rep"},{"key":"2026012114101801700_ehf214347-bib-0032","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0033","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0034","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0035","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"key":"2026012114101801700_ehf214347-bib-0036","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114101801700_ehf214347-bib-0037","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"2026012114101801700_ehf214347-bib-0038","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","article-title":"Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction","volume":"6","author":"Hummel","year":"2013","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2010\/65017966\/eschf_10_3_2010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2010\/65017966\/eschf_10_3_2010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:11:29Z","timestamp":1769022689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/2010\/8304688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4,11]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14347","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"2023-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}